Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma

Summary

The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma. Study details include: * The study duration for each participant will be approximately 10 weeks. * The duration of IMP administration will be approximately 4 weeks.

Timeline

Start

2024-08-05

Primary completion

2025-10-15

Completion

2025-10-15

Publications

• Dosanjh DPS, Darrah E, Jensen TJ, Jevnikar Z, Halvorson A, Cardner M, Hughes R, Grant SS, Platt A, Brightling CE. ARTEMISIA: a mechanistic study of a novel Janus kinase 1 inhibitor to advance molecular understanding and precision medicine in asthma. Respir Res. 2025 Jul 2;26(1):233. doi: 10.1186/s12931-025-03309-3.

Drugs

Indications